nitisinone (Orfadin)

1.	Sjolander, Diane E: 1 article (04/2006)
2.	Kobrinsky, Nathan L: 1 article (04/2006)
3.	Rubin, Benjamin I: 1 article (06/2005)
4.	Kaiser-Kupfer, Muriel I: 1 article (06/2005)
5.	Perry, Monique B: 1 article (06/2005)
6.	O'Brien, Kevin: 1 article (06/2005)
7.	Gahl, William A: 1 article (06/2005)
8.	Gerber, Lynn H: 1 article (06/2005)
9.	Bernardini, Isa: 1 article (06/2005)
10.	Tsilou, Ekaterina: 1 article (06/2005)

Related Diseases

1.	Alkaptonuria 06/01/2005 - "We investigated the safety and the HGA-depleting efficacy of nitisinone in an open-label, single-center study of 9 alkaptonuria patients (5 women, 4 men; 35-69 years of age) over the course of 3 to 4 months" 06/01/2005 - "We conclude that low-dose nitisinone effectively reduced urinary HGA levels in patients with alkaptonuria" 06/01/2005 - "Use of nitisinone in patients with alkaptonuria." 06/01/2005 - "Nitisinone, an inhibitor of the enzyme 4-hydroxyphenylpyruvate dioxygenase, can drastically reduce urinary excretion of HGA in individuals with alkaptonuria" Get all the results and reference details, order at left...
2.	Hepatocellular Carcinoma (Hepatoma) 05/01/2008 - "OBJECTIVES: This review examines recent pharmacological and clinical literature on nitisinone, and assesses its impact as a pharmacological treatment for hereditary tyrosinaemia type 1. METHODS: English language literature from MedLine and EmBase for nitisinone was searched from 1990 to 2008 for all papers relevant to the use of nitisinone in hereditary tyrosinaemia type 1. CONCLUSIONS: Nitisinone can prevent the development of liver disease and significantly reduce the risk of developing hepatocellular carcinoma; however, vigorous surveillance for the development of HCC needs to be continued lifelong." 12/01/2003 - "Administration of 2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione (NTBC) corrects the tyrosinemia phenotype, but does not prevent development of hepatocellular carcinoma" 01/01/2006 - "Pharmacologic treatment with nitisinone, a peroral inhibitor of the tyrosine catabolic pathway, offers an improved means of treatment for patients with HT-I. However, longer follow-up periods are needed to establish the role of this drug in ultimately protecting patients from end-stage organ involvement and hepatocellular carcinoma" Get all the results and reference details, order at left...
3.	Rickets (Rachitis) 06/01/2008 - "Four children had clinical rickets at presentation (which improved), of whom one had nephrocalcinosis, which did not reverse on nitisinone" Get all the results and reference details, order at left...
4.	Neuroblastoma 04/01/2006 - "Nitisinone may be a promising agent in metastatic neuroblastoma." 04/01/2006 - "Nitisinone blocks the tyrosine pathway and may be effective in treating neuroblastoma" 04/01/2006 - "Response of metastatic recurrent neuroblastoma to nitisinone: a modulator of tyrosine metabolism." Get all the results and reference details, order at left...
5.	Nephrocalcinosis 06/01/2008 - "Four children had clinical rickets at presentation (which improved), of whom one had nephrocalcinosis, which did not reverse on nitisinone" Get all the results and reference details, order at left...
14 Diseases and 16 more articles analyzed in the Research Interface, order at left...

Related Drugs and Biologics

1.	Tyrosine (L-Tyrosine)
2.	Phenylalanine (L-Phenylalanine)
3.	Acids
4.	succinylacetone
5.	4-Hydroxyphenylpyruvate Dioxygenase
6.	Dioxygenases
7.	Cyclohexane
8.	4-hydroxyphenylpyruvic acid
8 Drugs and Important Bio-Agents and 7 more articles analyzed in the Research Interface, order at left...

Research Interface

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.

Unlimited Disease, Drug and Therapy Search
2 clicks from Disease to Drug to Evidence
Trial References
All the Positive Outcomes
Detailed Relationship Timeline Charts
Full Article Reference Details
Includes Mobile Interface Subscription
One-click to FDA Products/Patents
Request Institution License details >>

Price:

$490.00 access via web interface, 1 year subscription

Proceed to Checkout >>

Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.

Access from any web enabled PDA or Phone
Trial references
All the Positive Outcomes
Drug and Therapy searches
Full Article Reference Details
Try Mobile Interface >>

Price:

$45.00 access via "curehunter.com/m", 1 year subscription

Proceed to Checkout >>